Dr. Keith Brenner, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 558
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Johns Hopkins University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NJ license 25MA09379400 · NY license 242319
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hackensack University Medical Center Hackensack, NJ
- Jersey Shore University Medical Center Neptune, NJ
Medical groups
- Hackensack Meridian Health Medical Group - Specialty Care PC (1,922 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 558
- Services billed
- 1,554
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 298 | 184 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 189 | 99 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 133 | 72 |
| Critical care, first 30-74 minutes | 122 | 43 |
| Test to determine lung volumes using gas dilution or washout | 114 | 111 |
| Test to examine how well the lungs exchange gases | 113 | 111 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 100 | 99 |
| New patient office or other outpatient visit, 45-59 minutes | 95 | 95 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 55 | 53 |
| New patient office or other outpatient visit, 60-74 minutes | 32 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Hackensack, NJ | 142 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Hackensack, NJ | 100 |
| Prednisone Other prescribers in Hackensack, NJ | 73 |
| Azithromycin Other prescribers in Hackensack, NJ | 55 |
| Fluticasone Propionate Other prescribers in Hackensack, NJ | 50 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Hackensack, NJ | 48 |
| Montelukast Sodium Other prescribers in Hackensack, NJ | 40 |
| Ofev (nintedanib esylate) | 34 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Hackensack, NJ | 28 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Hackensack, NJ | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 59 payments worth $1,393 in total to this clinician.
| GlaxoSmithKline, LLC. | $340 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $285 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $166 |
| Ambu Inc. | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | $86.77 |
| Verona Pharma, Inc. | $84.68 |
| Viatris Specialty LLC | $79.46 |
| La Jolla Pharmaceutical Company | $39.26 |
| Food and Beverage | $1,393 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $20,950 in research payments for these studies, mostly to the institutions running them.
- A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibro…
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.